Smartlab Europe

Press Releases

Nutrition and health bars expand market share by tying into wellness, athleticism

Nutrition and health bars are stealing market share from the category leading snack and cereal bars in part because they tie into the health and wellness trend dominating many consumers’ purchasing decisions in a way snack and cereal bars...

FDA approves two new drug treatments for diabetes mellitus

The U.S. Food and Drug Administration today approved Tresiba (insulin degludec injection) and Ryzodeg 70/30 (insulin degludec/insulin aspart injection) to improve blood sugar (glucose) control in adults with diabetes mellitus. According to the Centers for Disease...

AstraZeneca and Tianjin Medical University sign cardiovascular research collaboration in China

AstraZeneca today announced the signing of a research collaboration in the area of cardiovascular diseases (CVDs) with Tianjin Medical University (TMU), one of China’s leading medical and scientific institutions. The research agreement focuses on exploring novel...

AstraZeneca and Orca Pharmaceuticals announce research collaboration to identify best-in-class ROR? inhibitors to treat auto-immune diseases

AstraZeneca and Orca Pharmaceuticals, a UK based biopharmaceutical company, today announced a three year collaboration to develop inhibitors of retinoic acid–related orphan nuclear receptor gamma (ROR?). Inhibitors of this receptor are believed to have potential against a wide range...

Horizon Pharma plc Announces the U.S. Patent and Trademark Office Issuance of an Additional Notice of Allowance With Claims Covering PENNSAID(R) (Diclofenac Sodium Topical...

Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced it received.   a Notice of Allowance...

Horizon Pharma plc to Present at the Morgan Stanley Global Healthcare Conference

Horizon Pharma plc (NASDAQ: HZNP) ("Horizon Pharma"), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, commenced an exchange offer for all of the outstanding...

Horizon Pharma plc Has Commenced Solicitation of Depomed, Inc. Shareholders for Calling of Special Meetings

Proposals to Be Considered Include Removal and Replacement of Entire Depomed Board of Directors and Repeal of Depomed, Inc.'s Recently Adopted Bylaw Amendments Horizon Pharma plc (NASDAQ: HZNP) ("Horizon Pharma"), a biopharmaceutical company focused on improving...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »